Abstract

Background Portosystemic collateral vessels are a sign of portal hypertension in liver cirrhosis. Esophageal collateral veins (ECVs) are one major type of portosystemic collateral vessels, which increase the recurrence of esophageal varices and bleeding after variceal eradication. However, the risk factors for ECVs were still unclear. Methods We retrospectively screened cirrhotic patients who had contrast-enhanced computed tomography (CT) images to evaluate ECVs and upper gastrointestinal endoscopic reports to evaluate gastroesophageal varices at our department. Univariate and multivariate logistic regression analyses were performed to explore the independent risk factors for ECVs. Odds ratios (ORs) were calculated. Subgroup analyses were performed in patients with and without previous endoscopic variceal therapy which primarily included endoscopic variceal ligation (EVL) and endoscopic injection sclerotherapy (EIS). Results Overall, 243 patients were included, in whom the prevalence of ECVs was 53.9%. The independent risk factors for ECVs were hepatitis C virus infection (OR = 0.250, p = 0.026), previous EVL (OR = 1.929, p = 0.044), platelet (OR = 0.993, p = 0.008), and esophageal varices needing treatment (EVNTs) (OR = 2.422, p = 0.006). The prevalence of ECVs was 60.8% (73/120) in patients undergoing EVL, 50% (10/20) in those undergoing EIS, and 47.5% (48/101) in those without previous endoscopic variceal therapy. The independent risk factors for ECVs were the use of nonselective beta-blockers (OR = 0.294, p = 0.042) and EVNTs (OR = 3.714, p = 0.006) in subgroup analyses of patients with and without previous endoscopic variceal therapy, respectively. Conclusions The presence of ECVs should be closely associated with the severity of portal hypertension in liver cirrhosis. Risk of ECVs might be increased by previous EVL.

Highlights

  • Esophageal varices (EVs) are the most common collaterals in advanced cirrhosis that are located inside the esophageal lumen [1]

  • We aimed to explore the risk factors for developing Esophageal collateral veins (ECVs) in cirrhotic patients with and without endoscopic esophageal variceal therapy

  • One hundred and forty-one patients underwent endoscopic variceal therapy, of whom 121 and 20 underwent endoscopic variceal ligation (EVL) and endoscopic injection sclerotherapy (EIS) as the last endoscopic variceal therapeutic approach, respectively. e interval between last endoscopic variceal therapy and computed tomography (CT) could not be calculated in 4 patients due to the lack of specific date. e information regarding use of NSBBs was available in 192 patients, of whom 16.1% (31/192) took NSBBs within 1 month before admission. e prevalence of ECVs on contrast-enhanced CT scans was 53.9% (131/243)

Read more

Summary

Introduction

Esophageal varices (EVs) are the most common collaterals in advanced cirrhosis that are located inside the esophageal lumen [1]. We aimed to explore the risk factors for developing ECVs in cirrhotic patients with and without endoscopic esophageal variceal therapy. Esophageal collateral veins (ECVs) are one major type of portosystemic collateral vessels, which increase the recurrence of esophageal varices and bleeding after variceal eradication. Subgroup analyses were performed in patients with and without previous endoscopic variceal therapy which primarily included endoscopic variceal ligation (EVL) and endoscopic injection sclerotherapy (EIS). E prevalence of ECVs was 60.8% (73/120) in patients undergoing EVL, 50% (10/20) in those undergoing EIS, and 47.5% (48/101) in those without previous endoscopic variceal therapy. E independent risk factors for ECVs were the use of nonselective beta-blockers (OR 0.294, p 0.042) and EVNTs (OR 3.714, p 0.006) in subgroup analyses of patients with and without previous endoscopic variceal therapy, respectively.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call